Treatment of severe traumatic brain injury with human bone marrow mesenchymal stem cell extracellular vesicles: a case report

After moderate improvement with conventional therapy, the substantial improvement observed following introduction of the IP suggests that hBM-MSC EVs may offer a novel and safe means to improve TBI patient outcomes. Appropriate randomized, controlled clinical trials to conclusively evaluate this therapeutic option are indicated.